author-photo

Michio Inukai

Kagawa University

58

Papers

487

Citations

Citation Trend

Filter By

Papers (45) Sort By

Journal Conference Others

P-193 Final results of hepatectomy followed by adjuvant chemotherapy with 3-month capecitabine plus oxaliplatin for colorectal cancer liver metastases: A multicenter phase 2 study

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Hepatectomy Followed by Adjuvant Chemotherapy with 3‐Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases

2021 Oncologist
Show All
- Source
- Cite
- Save
Citations (0)
A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI).

2020 International Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Hepatectomy followed by adjuvant chemotherapy with capecitabine plus oxaliplatin for three months for colorectal cancer liver metastases: A multicenter phase 2 study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
FOLFIRI plus bevacizumab (bev) as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) who have failed first-line bev plus oxaliplatin-based therapy: The randomized phase III EAGLE study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
FOLFIRI plus 5 mg/kg of bevacizumab versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE Study).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P-053Updated analysis of induction & maintenance adjuvant chemotherapy with 3-month oxaliplatin-based regimen followed by 3 months capecitabine in patients with stage III and high-risk stage II colorectal cancer :(JSWOG C2)

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.

2016 Drug Design Development and Therapy
Show All
- Source
- Cite
- Save
Citations (4)
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study

2016 BMJ Open
Show All
- Source
- Cite
- Save
Citations (4)
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (28)